• Intelicare nabs MercyCare contract for its AI sensor tech
  • Telix scores TGA approval for prostate cancer imaging product
  • MGC receives Israeli approval for COVID treatment dosing study


Intelicare Holdings (ASX:ICR)

Intelicare jumped 35.41% today after signing a $170,000 contract with MercyCare to provide its AI-based smart tech to help clients live independently.

MercyCare helps over 2,400 seniors live independently in their own homes and using the in-home sensor tech, will be able to access their clients’ 24/7 health and wellbeing data.

The technology includes the InteliCare Pro Dashboard for carers to enable personalised services, reduced intrusion and maintain independence while monitoring their physical and mental health for early signs of deterioration.

“MercyCare is a highly respected organisation that understands the importance of innovation and smart technology when seeking care solutions. This contract reflects InteliCare making substantial traction in the aged care sector thanks to our continued investment in creating innovative and scalable solutions that empower service providers with clear and comprehensive data,” InteliCare CEO Jason Waller said.

MercyCare has committed to purchasing a minimum of 125 units, with buy back terms at the 12-month anniversary for unused systems.


Telix Pharmaceuticals (ASX:TLX)

Telix rose 4.51% after announcing that the Australian Therapeutic Goods Administration (TGA) has approved Illuccix® (TLX591-CDx), the company’s lead prostate cancer imaging product for:

  • Patients with prostate cancer who are at risk of metastasis and who are suitable for initial definitive therapy and;
  • Patients with prostate cancer who have suspected recurrence based on elevated serum prostate specific antigen (PSA) level.

The company says the TGA approval facilitates widespread clinical access to prostate cancer imaging for all men across Australia including rural and regional areas, enabling availability of state-of-the-art PSMA PET imaging across the country.

“This new mode of imaging has been recognised in leading clinical practice guidelines as superior to conventional imaging with CT1 or MRI2, for the staging of prostate cancer,” Telix president APAC Dr David Cade said.

“Illuccix attaches to prostate cancer cells expressing PSMA and can be picked up by a PET scanner, giving physicians the ability to visualise tumour cells, including very small metastases, wherever they are in the body.”


MGC Pharmaceuticals (ASX:MXC)

Up 2.08% today was MGC Pharma, after receiving approval from the Israeli Ministry of Health for its Dosing Study for CimetrA treatment for the effects of COVID-19.

MGC Pharma will recruit 240 patients into the study in sites located in Israel, South Africa, the USA, and Russia, and will continue to observe patients enrolled in the trial for the 28-day follow-up period in order to ensure that data is not impacted by the effects of either long or post-COVID.

“This latest dosage study is the latest step as we move closer to being in a position to apply for marketing authorisation for CimetrA in territories across the globe,” MGC Pharma co-founder and managing director Roby Zomer said.

“We believe that CimetrA will prove to be a vitally important drug in the treatment of COVID-19 going forward, and look forward to sharing the results of the study in due course, along with further steps towards providing COVID-19 patients and governments across the world a cost-effective treatment to fast-track patient recovery and minimise the massive cost burden of long-term hospitalisation.”


Immutep (ASX:IMM)

Up 1.70% today was Immutep, after being granted a Chinese patent for its lead product candidate eftilagimod alpha (efti).

The patent ‘Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response’ follows the grant of European, Japanese and US patents.

The claims of the new patent relate to methods of use of (a) Immutep’s technology and (b) a chemotherapy agent in combination for the manufacture of a preparation for the treatment of cancer.

“We are making good progress building our global patent estate around our Lag-3 development pipeline, including lead candidate efti which has delivered promsing clinical data in various settings,” CEO Marc Voigt said.

“We will continue to make these important investments and are especially pleased to be working so closely with our Chinese partner, EOC Pharma, as they expand their clinical development of efti for the Chinese market.”